Black Diamond Therapeutics, Inc. Share Price OTC Markets
Equities
BDTX
US09203E1055
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.88 USD | 0.00% |
|
0.00% | 0.00% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 28Cr 2.34TCr |
---|---|---|---|---|---|
Net income 2024 * | -8.1Cr -676.63Cr | Net income 2025 * | -11Cr -918.88Cr | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.39
x | P/E ratio 2025 * |
-2.98
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.68% |
Managers | Title | Age | Since |
---|---|---|---|
Elizabeth Buck
FOU | Founder | 49 | 01/14/01 |
Mark Velleca
CEO | Chief Executive Officer | 60 | 09/21/09 |
Fang Ni
DFI | Director of Finance/CFO | 37 | 04/20/04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Velleca
CEO | Chief Executive Officer | 60 | 09/21/09 |
Ali Behbahani
BRD | Director/Board Member | 45 | 01/18/01 |
Garry Menzel
BRD | Director/Board Member | 59 | 01/14/01 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.08% | 12TCr | |
+20.09% | 11TCr | |
+8.24% | 2.28TCr | |
-20.52% | 2.07TCr | |
-16.19% | 1.65TCr | |
-12.78% | 1.64TCr | |
-44.35% | 1.58TCr | |
+1.75% | 1.35TCr | |
+69.45% | 1.17TCr |
- Stock Market
- Equities
- BDTX Stock
- BDTX Stock